A pipeline powered bypassion

pipeline

Pre-Clinical

Phase 1

Phase 2

Phase 3
SKELETAL MUSCLE
Tirasemtiv (ALS)

ASTELLAS OPTION*
CK-2127107 (SMA)

ASTELLAS COLLABORATION
CK-2127107 (COPD)

ASTELLAS COLLABORATION
CK-2127107 (ALS)

ASTELLAS COLLABORATION
CK-2127107 (Frailty)

ASTELLAS COLLABORATION
CARDIAC MUSCLE
Omecamtiv Mecarbil (heart failure)

AMGEN COLLABORATION
Research
Next Generation Cardiac Muscle Activators

AMGEN COLLABORATION
Next Generation Skeletal Muscle Activators

ASTELLAS COLLABORATION
Other Muscle Biology Directed Research

type

indication

phase

SKELETAL MUSCLE

Tirasemtiv (ALS) CK-2127107 (SMA) CK-2127107 (COPD) CK-2127107 (ALS) CK-2127107 (Frailty)

3 2 2 2 1

CARDIAC MUSCLE

Omecamtiv Mecarbil (heart failure)

Research

Next Generation Cardiac Muscle Activators Next Generation Skeletal Muscle Activators Other Muscle Biology Directed Research

Pre-Clinical Pre-Clinical Pre-Clinical

*Outside North America & Europe

Omecamtiv Mecarbil

In collaboration with Amgen, we are developing a novel therapy that may improve cardiac performance in patients with heart failure.

tirasemtiv

We’re focused on providing a new treatment option for people living with ALS, a progressive, degenerative, neuromuscular disease that affects movement and breathing.

CK-2127107

With Astellas, CK-107 is being developed as a potential treatment of SMA, a genetic disease affecting motor neurons in the spinal cord and the control of muscle movement.

We’re proud to be a leader in muscle biology and of our history of innovative scientific research. Read more about our work to develop medicines for people suffering from diseases that rob them of key muscle functions.

scientific events

The Cytokinetics team attends scientific events throughout the year. Learn more about where we will be discussing our research and clinical programs.